2-Oxoazepane-3-carboxylic acid | 96905-49-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酰胺类
• 英文名称: 2-Oxoazepane-3-carboxylic acid
• CAS: 96905-49-6
• 化学式: C₇H₁₁NO₃
• 分子量: 157.17
• InChiKey: MQXIMPGNIJCBHZ-UHFFFAOYSA-N

物化性质

• 沸点：
  431.4±38.0 °C(Predicted)
• 密度：
  1.218±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• [EN] HISTONE METHYLTRANSFERASE INHIBITORS<br/>[FR] INHIBITEURS DE L'HISTONE MÉTHYLTRANSFÉRASE
  申请人：GLOBAL BLOOD THERAPEUTICS INC

  公开号：WO2018119208A1

  公开（公告）日：2018-06-28

  The present disclosure provides certain angular tricyclic compounds that are histone methyltransi erases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinpathies (e.g., beta- thalassemia and sickle cell disease). Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

  本公开提供了一些角三环化合物，这些化合物是组蛋白甲基转移酶G9a和/或GLP的抑制剂，因此可用于治疗可以通过抑制G9a和/或GLP来治疗的疾病，例如癌症和血红蛋白病（例如，β-地中海贫血和镰状细胞病）。还提供了含有这些化合物的药物组合物以及制备这些化合物的方法。
• Thermoplastic composition based on polyphenylene ether and modified polyamide
  申请人：ENICHEM S.p.A.

  公开号：EP0618268A1

  公开（公告）日：1994-10-05

  A thermoplastic composition having an excellent balance of mechanical and thermal properties, an improved impact strength, a good flowability in the molten state and a good processability, comprising: at least a polyphenylene ether resin (A); at least a modified polyamide (B) obtained by anionic polymerization of a omega-lactam in the presence of an organic diisocyanate, and, optionally, a further polymeric additive.

  一种热塑性塑料组合物，具有优异的机械性能和热性能平衡、更高的冲击强度、熔融状态下良好的流动性和良好的加工性，包括 至少一种聚苯醚树脂 (A) 至少一种改性聚酰胺（B），由欧米茄内酰胺在有机二异氰酸酯存在下进行阴离子聚合而得，还可选 另一种聚合物添加剂。
• Histone methyltransferase inhibitors
  申请人：GLOBAL BLOOD THERAPEUTICS, INC.

  公开号：US10829452B2

  公开（公告）日：2020-11-10

  The present disclosure provides compounds of Formula (I) that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinpathies (e.g., beta thalassemia and sickle cell disease). Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds. where R1, alk, R2, Z1, Z2, X, R3, R4, B, a, and b are as described herein.

  本公开提供的式(I)化合物是组蛋白甲基转移酶G9a和/或GLP抑制剂，因此可用于治疗可通过抑制G9a和/或GLP治疗的疾病，如癌症和血红蛋白病（如β地中海贫血和镰状细胞病）。此外，还提供了含有此类化合物的药物组合物和制备此类化合物的工艺。 其中 R1、alk、R2、Z1、Z2、X、R3、R4、B、a 和 b 如本文所述。
• HISTONE METHYLTRANSFERASE INHIBITORS
  申请人：Global Blood Therapeutics, Inc.

  公开号：EP3558971B1

  公开（公告）日：2022-02-23
• PROCESS FOR PRODUCING MONOMER COMPOSITIONS AND USE OF THESE FOR PRODUCING A POLYAMIDE MOLDING
  申请人：Scherzer Dietrich

  公开号：US20120088899A1

  公开（公告）日：2012-04-12

  A process for producing an activated monomer composition comprising at least one lactam and/or lactone, one catalyst, and one activator permits storage of the resultant monomer composition, since this is stable with respect to polymerization. Said monomer composition is used inter alia in producing a polyamide molding via ring-opening, anionic polymerization.